Navigation Links
China Biologic Products to Attend Canaccord Genuity 30th Annual Growth Conference
Date:7/29/2010

TAI'AN, China, July 29 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic" or the "Company"), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China ("PRC"), operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. ("Taibang") and Guiyang Dalin Biologic Technologies Co., Ltd. ("Dalin") and its equity investment in Xi'an Huitian Blood Products Co., Ltd. ("Huitian"), today announced that Mr. Y. Tristan Kuo, the Company's Chief Financial Officer, will present at the Canaccord Genuity 30th Annual Growth Conference (the "Conference"), on August 11, 2010 at 1:00 p.m. ET. The Conference will be held from August 10-12, 2010 at the InterContinental Boston Hotel, in Boston, Massachusetts. Mr. Kuo will also be available for one on one meetings with investors and analysts at the conference.

For more information about the conference and registration, please contact Nadine Miller at nmiller@canaccordgenuity.com .

About China Biologic Products, Inc.

China Biologic Products, Inc., through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China. Please see the Company's website http://www.chinabiologic.com for additional information.

    For more information, please contact:

    Company Contact:
     Mr. Y. Tristan Kuo
     Chief Financial Officer
     China Biologic Products, Inc.
     Tel:   +86-538-6202206
     Email: IR@chinabiologic.com
     Web:   http://www.chinabiologic.com

    Investor Relations Contact:
     Mr. Kalle Ahl, Account Manager
     CCG Investor Relations
     Tel:   +1-646-833-3417
     Email: kalle.ahl@ccgir.com
     Web:   http://www.ccgirasia.com

     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE China Biologic Products, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
3. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
4. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
5. China Biologic Products Announces Second Quarter 2008 Results Conference Call
6. China Medicine Announces Strong Second Quarter 2008 Results
7. China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee
8. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
9. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
10. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
11. China Biologic Products Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), reported today ... a total of 10,672,750 common share purchase warrants have been ... from the exercise of these warrants totalled $1,387,458 and 10,672,750 ... ... this expression of confidence by our warrant holders. This infusion ...
(Date:2/27/2017)... , February 27, 2017 ... Stock-Callers.com for evaluation today, and they are: Anthera Pharmaceuticals ... Biosciences of California Inc. (NASDAQ: PACB), and Conatus Pharmaceuticals ... article on ETF Trends, market observers are growing more ... administration could enact reforms to free cash held overseas ...
(Date:2/27/2017)... , Feb. 27, 2017 Fluxion Biosciences ... Spain has been appointed as a Certified ... The IsoFlux system will be used in Genetracer Biotech,s ... to lung and colon cancer, with plans to move ... laboratory is utilizing Fluxion,s IsoFlux System to isolate, recover, ...
(Date:2/27/2017)... , ... February 27, 2017 , ... The Catalyst ... a few in the Midwest offering premix services and private label organic services. , ... laying hens, according Jos Zamzow, chief operating officer of Dynamite Marketing, which owns the ...
Breaking Biology Technology:
(Date:2/26/2017)... 25, 2017  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announces the ... "Too often, too many offenders return ... jails are trying to tackle this ongoing problem ... and family members. While significant steps are underway, Securus ...
(Date:2/16/2017)...  Genos, a community for personal genetic discovery ... Laboratory Accreditation from the College of American Pathologists ... that meet stringent requirements around quality, accuracy and ... "Genos is committed to maintaining the highest ... to be receiving CAP accreditation," said Jill ...
(Date:2/9/2017)... 9, 2017 The biomass boiler market report ... biomass boiler market globally in terms of revenue (US$ ... The market for biomass boilers has been segmented on ... and country/region. The market based on feedstock type, has ... biogas & energy crops, urban residues, and others. On ...
Breaking Biology News(10 mins):